ipilimumab + etoposide + cisplatin + carboplatin

A four-drug combination regimen that includes **ipilimumab** (a monoclonal antibody that targets cytotoxic T-lymphocyte antigen-4 [CTLA-4]), **etoposide** (a topoisomerase II inhibitor), **cisplatin** (a platinum-based alkylating agent), and **carboplatin** (another platinum-based alkylating agent). This combination has been studied in the context of first-line treatment for patients with **extensive-stage small cell lung cancer (ED-SCLC)**, in which ipilimumab is added to the standard chemotherapy backbone of etoposide and a platinum compound (cisplatin or carboplatin). The key mechanism of ipilimumab is enhancement of T-cell mediated immune responses against cancer, while etoposide, cisplatin, and carboplatin directly damage tumor cell DNA. The combination was assessed in a large phase III trial (CA184-156) but did not significantly improve overall survival compared to chemotherapy alone[1][3].